ABCD: Update of the 2009 guidelines on prevention and management of feline infectious diseases

A bacterium-like particle vaccine displaying protective feline herpesvirus 1 antigens can induce an immune response in mice and cats

Feline herpesvirus 1 (FHV-1) is a highly transmissible virus that mainly causes ocular and upper respiratory infections in cats and seriously threatens the health of domestic cats and captive or wild cats (such as tigers, cheetahs, and lions). Vaccination is crucial to reduce the incidence rate and mortality of cats infected with FHV-1. In this study, three bacterium-like particles (BLPs) displaying the gB, gC, and gD proteins of FHV-1 were constructed based on a gram-positive enhancer matrix-protein anchor (GEM-PA) surface display system. Indirect immunofluorescence assay, western blot, and electron microscopy results showed that gB, gC or gD protein of FHV-1 was successfully displayed on the surface of GEM particles. Additionally, we designed one more BLPs, designated gB&gC&gD-GEM, which consisted of a mixture of gB-GEM, gC-GEM, and gD-GEM at a protein content ratio of 1:1:1. Mice were immunized with the four BLPs mixed with Gel02 adjuvant, and the results indicated that neutralizing antibody level in the gB&gC&gD-GEM group was superior than those in the other groups. Moreover, gB&gC&gD-GEM significantly increased the secretion of cytokines, as well as the activation and maturation of B cells. It also boosted the production of central memory T cells among CD4 + and CD8 + T cells. Moreover, gB&gC&gD-GEM mixed with Gel02 adjuvant provoked an antibody response in cats. In conclusion, the BLPs vaccine prepared from gB&gC&gD-GEM induced specific humoral and cellular immune responses to FHV-1 and be used as a potential vaccine candidate for the control of FHV-1 infection in cats.

Impact of the Application of Gaseous Ozone on Selected Pathogens Found in Animal Shelters and Other Facilities

Correctly selecting disinfection procedures is crucial in facilities housing a high number of animals as it directly affects their health. The aim of this study was to verify the virucidal effect of gaseous ozone delivered by commercially available generators under controlled experimental conditions on a selection of viral pathogens (feline coronavirus, canine coronavirus, feline calicivirus, feline parvovirus) commonly found in shelters and other facilities. Two ozone generators with outputs of 3.5 g/h and 20 g/h were used to produce ozone. Virus viability after the application of ozone was evaluated by examining for typical pathogen-specific cytopathic effects on the CRFK (Crandell-Rees Feline Kidney) cell line post-incubation. No cytopathic effect was observed in feline coronavirus after the 2-h application of ozone; in canine coronavirus, the absence of a cytopathic effect was observed after the 4-h application of ozone. The absence of a cytopathic effect in feline calicivirus was observed after the 6-h application of ozone; the viability of feline parvovirus was not impaired even by the 6-h application of ozone. The results of the study confirm lower resistance to the application of gaseous ozone in enveloped viruses.

Comparison of the local safety of two multi-component feline vaccines, adjuvanted (1 mL) versus non-adjuvanted at reduced volume (0.5 mL), using computed tomography imaging

In 2020, a new 0.5 mL presentation of PUREVAX® RCP FeLV was registered and introduced in Europe. The objectives of this study were to investigate the local safety of this non-adjuvanted vaccine at reduced volume by classical methods (clinical examination, histopathology) and to evaluate the suitability of an alternative non-invasive methodology, the computed tomography (CT). For this purpose, the course of local reactions was assessed for 3 months after subcutaneous injection of PUREVAX® RCP FeLV 0.5 mL and compared to an adjuvanted vaccine, LEUCOFELIGEN® FeLV/RCP 1.0 mL. Injection site reactions consisted mainly of swelling reactions, which were more frequent, more pronounced and long-lasting in the adjuvanted vaccine group. Microscopically, in this group, moderate to severe inflammatory reactions were observed on day 7 (D7) and D21 post-injection and still present on D84, while mild inflammatory lesions were observed in the non-adjuvanted vaccine group only on D7 and D21. With the adjuvanted vaccine, inflamed areas were measurable by CT scan in all cats on D7 and D21, whereas they were detected only on D7 and only in 20 % of cats from the non-adjuvanted vaccine group. Besides the higher frequency, the mean inflamed volume was nearly 300 times larger in adjuvanted vaccine group on D7. Using different methodologies, the favorable safety profile of PUREVAX® RCP FeLV 0.5 mL was confirmed. Furthermore, the vaccine is aligned with current vaccination guidelines by inducing less inflammatory reactions, being adjuvant-free and injectable under a reduced volume, thus improving the convenience of administration in recommended sites (eg, legs). CT scan proved to be a suitable non-invasive method for the experimental follow-up of injection site reactions, yielding results consistent with clinical assessment and histopathology on D7 and D21. CT scan substantiated large differences between the investigated vaccines with a more prominent inflammatory reaction after injection of an adjuvanted vaccine.

Evaluation of safety and immunogenicity of feline vaccines with reduced volume

A non adjuvanted vaccine against feline herpesvirus, feline calicivirus, feline panleucopenia and feline leukemia has been formulated in reduced volume (0.5 ml) with the same antigen content as the conventional 1 ml presentation. This paper reports studies evaluating the safety and the immunogenicity of this reduced volume vaccine in comparison with the conventional volume vaccine. The safety of both vaccines was evaluated in a small sized laboratory trial. It was further tested in a randomized controlled field trial on a total of 398 cats. Immediate and delayed local and systemic adverse events were monitored after vaccination. The immunogenicity of each vaccine was also checked by serological antibody responses against the vaccines antigens during the laboratory trial. These studies showed that the 0.5 ml vaccine was well tolerated in cats, inducing less local events, while keeping the same immunogenicity as the corresponding 1 ml vaccine. Reducing the volume of the vaccine is a way to improve the convenience of administration and to help following vaccination guidelines with the aim of reducing the incidence of adverse events following vaccination.

Prevalence of serum antibody titres against feline panleukopenia, herpesvirus and calicivirus infections in stray cats of Milan, Italy

The aim of the study was to determine the seroprevalence of feline panleukopenia virus (FPV), feline herpesvirus type 1 (FHV-1) and feline calicivirus (FCV) in stray colony cats from Milan, Italy. Cats were divided in groups based on age, gender, reproductive status, health status and colony of origin. Blood samples were tested with an in-clinic ELISA test. The possible presence of a link between the antibody titre or the presence of seropositive results and the independent variables (age, gender, reproductive status, health status and colony location) was assessed by means of multinomial and univariate logistic regression models, respectively. Seroprevalence of 85.4% was reported for FCV. The diffusion of the other two pathogens in the cat population was much lower compared to FCV, with 45.7% and 37.1% seroprevalence observed for FPV and FHV-1, respectively. An increase of antibody titres from kitten to senior was generally observed for the three pathogens. Age was a statistically significant variable for FHV-1, with senior cats significantly associated with higher antibody titres and higher percentages of seropositive animals compared to younger age groups. Neutered cats had significantly higher antibody titres and showed significantly higher FHV-1 seroprevalences compared to sexually intact cats. Colonies from two of the nine administrative districts of Milan showed significantly higher FPV seroprevalences compared to the others. No other significant differences were observed. Our results, based on cats belonging to 70 different colonies located in urban areas far from each other, suggest that the three viruses circulate in the feline population of stray cats in Milan. The feline calicivirus represents the most common circulating pathogen, as observed also in other studies worldwide. Finally, our results suggest that stray cats may be not adequately protected against FPV, FHV-1 and FCV and vaccination could be a possible strategic solution, especially for FPV.

In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates

Equid alphaherpesvirus 3 (EHV3) is the etiological agent of equine coital exanthema (ECE), which is a venereal, highly contagious disease, characterized by the formation of papules, vesicles, pustules and ulcers on the external genitalia of mares and stallions. EHV3 remains in a latent state after a successful infection and there are latently infected animals in which the virus is reactivated and generally re-excreted subclinically. There are no available vaccines for this condition and prevention is based on the clinical examination of mares prior to mating, which allows to segregate those showing clinical signs. As this approach does not eliminate the risk of contagion in stallions from subclinically infected mares, there is a need for a specific EHV3 treatment. Nowadays, there exist various antiviral compounds of proven effectiveness for other alphaherpesviruses affecting humans and animals. The aim of the present study was to compare the efficacy of three antiviral compounds, acyclovir, ganciclovir and cidofovir against EHV3 in vitro, and to assess their efficacy against six EHV3 Argentinian field isolates. To determine the efficacy of these compounds in vitro, three parameters were analyzed: reduction of plaque number, reduction of plaque size and reduction of viral production. Additionally, the effectiveness of the three compounds at an optimum concentration previously determined in this study was investigated for the EHV3 field isolates. Based on our results, ganciclovir was the most potent antiviral compound to reduce EHV3 replication in vitro and may thus be a valuable candidate for treatment and prevention of ECE in mares and stallions.

Effect of a synthetic feline facial pheromone product on stress scores and incidence of upper respiratory tract infection in shelter cats

OBJECTIVE To determine whether a synthetic feline facial pheromone product would decrease stress scores and upper respiratory tract infection (URI) incidence in shelter-housed cats. DESIGN Randomized controlled clinical trial. ANIMALS 336 stray, feral, owner-relinquished, or legally impounded cats at 2 animal shelters in northern California. PROCEDURES 5 cat holding rooms (3 at shelter A and 2 at shelter B) were used. A diffuser containing either synthetic pheromone or placebo was randomly assigned to each room, and cats were exposed for a 21-day period. Data collected on each cat included signalment, daily stress scores, and daily URI incidence. After 21 days, diffusers were removed for a 7-day washout period. The type of diffuser in each room was switched, and data were collected for another 21 days. Findings were statistically compared between exposure types and other groupings. RESULTS Cox proportional hazard analysis revealed no significant difference between exposure (pheromone or placebo) and URI incidence. Mixed-effects ordinal logistic regression revealed no significant relationship between exposure and daily stress scores. Three covariates had significant ORs: number of days in holding (OR, 0.80; 95% confidence interval [CI], 0.76 to 0.84), owner-relinquished versus stray (OR, 3.25; 95% CI, 1.18 to 8.94), and feral versus adult cat room at shelter A (OR, 11.10; 95% CI, 4.47 to 27.60). CONCLUSIONS AND CLINICAL RELEVANCE No evidence was found that the evaluated synthetic feline facial pheromone product had any effect on stress scores or URI incidence in shelter-housed cats. Therefore, other established methods for stress and URI reduction should be used in shelter settings.

Clinical improvement in feline herpesvirus 1 infected cats by oral low dose of interleukin-12 plus interferon-gamma

Feline herpesvirus 1 (FHV-1) is a widespread cat pathogen inducing rhinitis, conjunctivitis and corneal ulcers. To alleviate acute FHV-1-induced disease, antiviral agents are used often with antibiotics. But sometimes, these treatments, as well as conventional doses of cytokines have moderate efficacy and/or collateral effects. Herein we have investigated the effects of low dose interleukin (IL)-12 plus interferon (IFN)-gamma, prepared by Sequential Kinetic Activated (SKA), on the treatment of FHV-1 infection. Twenty-five, unvaccinated FHV-1-positive cats were recruited into a prospective, randomized, placebo-controlled, double-blinded clinical trial. Fifteen cats were treated for 6 months with oral low doses of SKA IL-12 plus IFN-gamma and 10 cats were treated with placebo. At 1, 6 and 12 months (follow-up) after the beginning of treatment, clinical assessment, PCR assay and blood count were carried out. At follow-up, in treated group, we observed significant (p<0.05) improvements in clinical signs and PCR became negative in 12/15 cats (80%). In placebo, 10/10 cats were PCR-positive, with improvements (30%) or worsening (70%) in clinical signs. Blood values were normal in both groups. Our results show that the low dose therapy, based on activated solutions of IL-12 plus IFN-gamma, represents a novel approach to treat FHV-1 infection in cats.

Something old, something new: Update of the 2009 and 2013 ABCD guidelines on prevention and management of feline infectious diseases

OVERVIEW

The ABCD has published 34 guidelines in two Special Issues of the Journal of Feline Medicine and Surgery (JFMS): the first in July 2009 (Volume 11, Issue 7, pages 527-620) and the second in July 2013 (Volume 15, Issue 7, pages 528-652). The present article contains updates and new information on 18 of these (17 disease guidelines and one special article 'Prevention of infectious diseases in cat shelters'). For detailed information, readers are referred to the guidelines published in the above-mentioned JFMS Special Issues.

Antiviral agents against equid alphaherpesviruses: Current status and perspectives

Equid herpesvirus infections cause respiratory, neurological and reproductive syndromes. Despite preventive and control measures and the availability of vaccines and immunostimulants, herpesvirus infections still constitute a major threat to equine health and for the equine industry worldwide. Antiviral drugs, particularly nucleoside analogues and foscarnet, are successfully used for the treatment of human alphaherpesvirus infections. In equine medicine, the use of antiviral medications in alphaherpesvirus infections would decrease the excretion of virus and diminish the risk of contagion and the convalescent time in affected horses, and would also improve the clinical outcome of equine herpesvirus myeloencephalopathy. The combined use of antiviral compounds, along with vaccines, immune modulators, and effective preventive and control measures, might be beneficial in diminishing the negative impact of alphaherpesvirus infections in horses. The purpose of this review is to analyse the available information regarding the use of antiviral agents against alphaherpesviruses, with particular emphasis on equine alphaherpesvirus infections.